Adam J Rosenberg1, Michael L Nickels2, Michael L Schulte2, H Charles Manning3. 1. Vanderbilt Center for Molecular Probes, Vanderbilt University Medical Center, Nashville, TN, USA; Vanderbilt University Institute for Imaging Science, Vanderbilt University Medical Center, Nashville, TN, USA. 2. Vanderbilt Center for Molecular Probes, Vanderbilt University Medical Center, Nashville, TN, USA; Vanderbilt University Institute for Imaging Science, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, USA. 3. Vanderbilt Center for Molecular Probes, Vanderbilt University Medical Center, Nashville, TN, USA; Vanderbilt University Institute for Imaging Science, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, USA; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA; Department of Neurosurgery, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Chemistry, Vanderbilt University, Nashville, TN, USA. Electronic address: henry.c.manning@vanderbilt.edu.
Abstract
INTRODUCTION: The natural amino acid l-Glutamine (Gln) is essential for both cell growth and proliferation. In addition to glucose, cancer cells utilize Gln as a carbon source for ATP production, biosynthesis, and as a defense against reactive oxygen species. The utilization of [11C]Gln has been previously reported as a biomarker for tissues with an elevated demand for Gln, however, the previous reports for the preparation of [11C]Gln were found to be lacking several crucial aspects necessary for transition to human production. Namely, the presence of unreacted precursor and the use of non-commercialized, custom built, reaction platforms. Herein, we report the development and utilization of methodology for the automated production of [11C]Gln that meets institutional criteria for human use. METHODS: The preparation of [11C]Gln was carried out on the GE FX2N platform. Briefly, after trapping of [11C]HCN with a solution of CsHCO3 in DMF, the [11C]CsCN was reacted with a commercially available precursor. This intermediate was then purified by HPLC and deprotected/hydrolyzed under acidic conditions. Following pH adjustment, the product was filtered to give the desired [11C]Gln as a sterile injectable. The resulting product was then analyzed for quality assurance. RESULTS: Automated production by this method reliably provides over 3.7 GBq (100 mCi) of [11C]Gln. The resulting final drug product was found to have a >99% radiochemical purity, <5% of D-Gln present, no detectable impurities, and the total preparation time was roughly 45 min from the end-of-bombardment. CONCLUSIONS: A fast, reliable and efficient automated radiosynthesis was developed using a commercially available module. Purifications used throughout allow for both a radiochemically and chemically pure final product solution of [11C]Gln.
INTRODUCTION: The natural amino acid l-Glutamine (Gln) is essential for both cell growth and proliferation. In addition to glucose, cancer cells utilize Gln as a carbon source for ATP production, biosynthesis, and as a defense against reactive oxygen species. The utilization of [11C]Gln has been previously reported as a biomarker for tissues with an elevated demand for Gln, however, the previous reports for the preparation of [11C]Gln were found to be lacking several crucial aspects necessary for transition to human production. Namely, the presence of unreacted precursor and the use of non-commercialized, custom built, reaction platforms. Herein, we report the development and utilization of methodology for the automated production of [11C]Gln that meets institutional criteria for human use. METHODS: The preparation of [11C]Gln was carried out on the GE FX2N platform. Briefly, after trapping of [11C]HCN with a solution of CsHCO3 in DMF, the [11C]CsCN was reacted with a commercially available precursor. This intermediate was then purified by HPLC and deprotected/hydrolyzed under acidic conditions. Following pH adjustment, the product was filtered to give the desired [11C]Gln as a sterile injectable. The resulting product was then analyzed for quality assurance. RESULTS: Automated production by this method reliably provides over 3.7 GBq (100 mCi) of [11C]Gln. The resulting final drug product was found to have a >99% radiochemical purity, <5% of D-Gln present, no detectable impurities, and the total preparation time was roughly 45 min from the end-of-bombardment. CONCLUSIONS: A fast, reliable and efficient automated radiosynthesis was developed using a commercially available module. Purifications used throughout allow for both a radiochemically and chemically pure final product solution of [11C]Gln.
Authors: Mohamed Hassanein; Matthew R Hight; Jason R Buck; Mohammed N Tantawy; Michael L Nickels; Megan D Hoeksema; Bradford K Harris; Kelli Boyd; Pierre P Massion; H Charles Manning Journal: Mol Imaging Biol Date: 2016-02 Impact factor: 3.488
Authors: Thomas M Jeitner; Eva Kristoferson; Juan A Azcona; John T Pinto; Clint Stalnecker; Jon W Erickson; Hank F Kung; Jianyong Li; Karl Ploessl; Arthur J L Cooper Journal: J Fluor Chem Date: 2016-10-20 Impact factor: 2.050
Authors: Wenchao Qu; Shunichi Oya; Brian P Lieberman; Karl Ploessl; Limin Wang; David R Wise; Chaitanya R Divgi; Lewis A Chodosh; Lewis P Chodosh; Craig B Thompson; Hank F Kung Journal: J Nucl Med Date: 2011-12-15 Impact factor: 10.057
Authors: Allison S Cohen; Joe Grudzinski; Gary T Smith; Todd E Peterson; Jennifer G Whisenant; Tiffany L Hickman; Kristen K Ciombor; Dana Cardin; Cathy Eng; Laura W Goff; Satya Das; Robert J Coffey; Jordan D Berlin; H Charles Manning Journal: J Nucl Med Date: 2021-04-30 Impact factor: 11.082